NGS Process Report
The NGS process space is extremely busy with many commercial players that provide sequencing reagents, instruments, and analysis solutions. An extensive analysis of this space highlights that as the sequencing technology has matured, the challenges have shifted toward data explosion and computing, data interpretation to gather and report actionable information, and information management.
This report is unique, in that it is not a predictive market research report, but rather builds on data gathered from the many end-user interviews and the data available in the scientific literature.
This specific analysis identified the obvious top players which includes Illumina on the instruments side (and to some extent on the reagents side), Thermo Fisher Scientific, and Pacific Biosciences; Illumina also offers a data analysis and interpretation solution via BaseSpace. Agilent technologies, Qiagen, and Thermo Fisher Scientific are the main actors on the reagents side, while on the analysis side we observe several providers that are strong in different areas of data analysis and interpretation. DNAnexus and Seven Bridges Genomics have emerged as open and flexible platforms for data analysis, Bluebee, Genalice, and Edico Genome as alternatives enabling fast DNA processing. On the data interpretation side we have several noteworthy companies such as Congenica, Ingenuity (Qiagen), Omicia, Station X, or WuXi NextCODE offering elegant analysis solutions, with Congenica, Ingenuity, Omicia, and WuXi NextCODE also being strong on the clinical data interpretation side. Alongside these established companies, we should not overlook the significant impact of open source tools that command a sizable share of the data analysis volume (~68% of all users still use in-house or open source tools for their analyses – some as standalone solutions and some in combination with commercially available offerings), such as the Broad Institute Scientific Community Software and Sanger Institute Tools and Software made available to the entire community.
Our data is substantiated with an analysis of the published NGS/sequencing literature, 28 interviews (19 end-users and nine industry representative interviews) highlighting product preferences for sample preparation and sample sequencing, customer/end-users unmet needs and challenges, and the brand perception users have for the different supplier companies and their products, plus an extensive comparative analysis of key players in the sequence data analysis and interpretation space.
The approach taken to decipher the NGS process and its components, as summarized within this report, was rooted in the following questions: who are the key commercial companies in this process, who are the end-users and what are their unmet needs and challenges, and when researching the analysis and interpretation side of the equation, what challenges need the commercial life science product providers address, and who addresses them how?
This 111 page NGS Process Report consists of 23 Figures, 39 Tables, and 17 company profiles (Agilent Technologies, Bina Technologies, Bluebee, CLC Bio (Qiagen), Congenica, DNAnexus, Edico Genome, Genalice, BaseSpace (Illumina), Ingenuity Systems (Qiagen), New England Biolabs, Omicia, Qiagen, Seven Bridges Genomics, Station X, Thermo Fisher Scientific, and WuXi NextCODE).
